The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.

But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.

But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.

The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.

The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.

Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.